MAM
BCRX icon

Martingale Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Martingale Asset Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.43M Buy
242,508
+185,979
+329% +$1.68M 0.06% 352
2026
Q1 		$538K Buy
+56,529
New +$439K 0.01% 619
2024
Q3 		– Sell
-54,055
Closed -$334K – 792
2024
Q2 		$334K Buy
54,055
+9,552
+21% +$52.7K 0.01% 678
2024
Q1 		$226K Buy
44,503
+28,466
+178% +$160K ﹤0.01% 757
2023
Q4 		$96.1K Buy
+16,037
New +$92.9K ﹤0.01% 778

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Martingale Asset Management's BCRX Position: Q2 2026 in Review

Martingale Asset Management increased its BioCryst Pharmaceuticals (BCRX) stake by 329% in Q2 2026, buying an estimated $1.68M and bringing the position to 242,508 shares worth $2.43M. The position accounts for 0.06% of the portfolio, ranked #352.

Martingale Asset Management first reported a position in BCRX in Q4 2023 and has held it in 5 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Martingale Asset Management held 242,508 shares of BioCryst Pharmaceuticals worth $2.43M as of Q2 2026.
  • Martingale Asset Management bought 185,979 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $1.68M.
  • BioCryst Pharmaceuticals made up 0.06% of Martingale Asset Management's portfolio in Q2 2026, its #352 holding.
  • Martingale Asset Management first reported a position in BioCryst Pharmaceuticals in Q4 2023 and has held it in 5 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Martingale Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.